A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome

Purpose

The primary purpose of the study is to demonstrate that lorcaserin has superior efficacy compared to placebo on percent change in frequency of convulsive seizures per 28 days in participants with Dravet syndrome.

Condition

  • Epilepsies, Myoclonic

Eligibility

Eligible Ages
Over 2 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

Participants must meet all of the following criteria to be included in this study: 1. Male or female, age 2 years and older at the time of informed consent 2. Diagnosis of epilepsy with Dravet syndrome 3. Has at least 4 convulsive seizures during the 4 weeks of baseline 4. Current treatment with antiepileptic drugs must be stable for at least 4 weeks before screening, and be expected to remain stable throughout the study

Exclusion Criteria

Participants who meet any of the following criteria will be excluded from this study: 1. Use of lorcaserin within 4 weeks before screening, or any history of it being discontinued due to lack of efficacy or adverse reactions 2. Use of fenfluramine within 2 months before screening, any history of lack of fenfluramine efficacy, or any history of valvulopathy at baseline with history of fenfluramine use 3. Recent or concomitant use of serotonergic medications or monoamine oxidase inhibitors 4. Presence of progressive central nervous system disease other than Dravet syndrome

Study Design

Phase
Phase 3
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Lorcaserin (Core Study and Open-label Extension Phase) 		Participants will be randomized to receive lorcaserin administered as an oral suspension, twice daily for 14 weeks during the core treatment period. Dose will be based on body weight as follows: target dose for participants weighing 10 to less than (<) 20, 20 to <40, and greater than or equal to (>=) 40 kilogram (kg) will be 5, 10, and 20 milligram per day (mg/day) respectively. Based on clinical response and tolerability and within 2 weeks of treatment, dose can be increased up to 10, 20 mg/day for participants weighing 10 to <20, 20 to <40 kg respectively. Participants completing the core treatment period will enter a 12-week extension phase and will receive lorcaserin.
  • Drug: Lorcaserin
    Lorcaserin oral tablet, administered as oral suspension.
    Other names:
    • E2023
Placebo Comparator
Placebo (Core Study) + Lorcaserin (Open-label Extension Phase) 		Participants will be randomized to receive lorcaserin matching placebo administered as an oral suspension, twice daily for 14 weeks during the core treatment period. Dose will be based on body weight as follows: target dose for participants weighing 10 to <20, 20 to <40, and >=40 kg will be 5, 10, and 20 mg/day respectively. Based on clinical response and tolerability and within 2 weeks of treatment, dose can be increased up to 10, 20 mg/day for participants weighing 10 to <20, 20 to <40 kg respectively. Participants completing the core treatment period will enter a 12-week extension phase and will receive lorcaserin.
  • Drug: Placebo
    Placebo matching to lorcaserin oral tablet, administered as oral suspension.
  • Drug: Lorcaserin
    Lorcaserin oral tablet, administered as oral suspension.
    Other names:
    • E2023

Recruiting Locations

Children's of Alabama / University of Alabama at Birmingham
Birmingham, Alabama 35226

More Details

Status
Recruiting
Sponsor
Eisai Inc.

Study Contact

Eisai Medical Information
1-888-274-2378
esi_medinfo@eisai.com